TransMedics Group, Inc. $TMDX Position Boosted by Zevenbergen Capital Investments LLC

Zevenbergen Capital Investments LLC raised its holdings in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 112.7% during the 3rd quarter, Holdings Channel reports. The fund owned 258,523 shares of the company’s stock after purchasing an additional 136,995 shares during the period. Zevenbergen Capital Investments LLC’s holdings in TransMedics Group were worth $29,006,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors also recently added to or reduced their stakes in TMDX. Charles Schwab Investment Management Inc. increased its holdings in shares of TransMedics Group by 2.3% during the first quarter. Charles Schwab Investment Management Inc. now owns 304,367 shares of the company’s stock valued at $20,478,000 after purchasing an additional 6,934 shares during the period. Nuveen LLC bought a new position in TransMedics Group in the 1st quarter valued at about $5,927,000. HighTower Advisors LLC increased its stake in TransMedics Group by 137.7% during the 1st quarter. HighTower Advisors LLC now owns 18,257 shares of the company’s stock valued at $1,228,000 after buying an additional 10,575 shares during the period. Raymond James Financial Inc. increased its stake in TransMedics Group by 135.8% during the 1st quarter. Raymond James Financial Inc. now owns 145,393 shares of the company’s stock valued at $9,782,000 after buying an additional 83,722 shares during the period. Finally, Algert Global LLC boosted its holdings in shares of TransMedics Group by 8.9% in the first quarter. Algert Global LLC now owns 13,674 shares of the company’s stock valued at $920,000 after acquiring an additional 1,120 shares in the last quarter. Institutional investors and hedge funds own 99.67% of the company’s stock.

TransMedics Group Stock Performance

Shares of TMDX opened at $127.67 on Friday. The company has a 50-day moving average of $127.74 and a two-hundred day moving average of $123.00. The stock has a market cap of $4.36 billion, a price-to-earnings ratio of 51.69 and a beta of 2.06. The company has a debt-to-equity ratio of 1.43, a current ratio of 7.69 and a quick ratio of 7.13. TransMedics Group, Inc. has a one year low of $55.00 and a one year high of $156.00.

TransMedics Group (NASDAQ:TMDX) last issued its quarterly earnings results on Wednesday, October 29th. The company reported $0.66 EPS for the quarter, beating the consensus estimate of $0.37 by $0.29. TransMedics Group had a net margin of 16.20% and a return on equity of 31.42%. The business had revenue of $143.82 million during the quarter, compared to the consensus estimate of $145.33 million. During the same quarter in the prior year, the firm earned $0.12 EPS. The firm’s quarterly revenue was up 32.2% on a year-over-year basis. On average, equities research analysts expect that TransMedics Group, Inc. will post 1 earnings per share for the current year.

Wall Street Analysts Forecast Growth

TMDX has been the topic of several recent analyst reports. Needham & Company LLC boosted their target price on TransMedics Group from $148.00 to $166.00 and gave the stock a “buy” rating in a report on Monday, December 8th. Weiss Ratings reissued a “hold (c)” rating on shares of TransMedics Group in a research note on Wednesday, October 8th. Stifel Nicolaus started coverage on TransMedics Group in a report on Thursday, September 4th. They issued a “hold” rating and a $115.00 price objective for the company. Evercore ISI assumed coverage on TransMedics Group in a research note on Tuesday, September 16th. They set an “outperform” rating and a $155.00 target price for the company. Finally, Jefferies Financial Group began coverage on shares of TransMedics Group in a research report on Monday, October 13th. They set a “buy” rating and a $145.00 price objective for the company. Six analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $144.25.

Insiders Place Their Bets

In related news, insider Anil P. Ranganath sold 3,000 shares of the company’s stock in a transaction on Tuesday, November 25th. The stock was sold at an average price of $145.22, for a total transaction of $435,660.00. Following the transaction, the insider directly owned 13,955 shares of the company’s stock, valued at approximately $2,026,545.10. The trade was a 17.69% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Edward M. Basile sold 4,142 shares of the firm’s stock in a transaction dated Wednesday, October 29th. The stock was sold at an average price of $130.45, for a total value of $540,323.90. Following the sale, the director owned 2,866 shares of the company’s stock, valued at $373,869.70. The trade was a 59.10% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 13,062 shares of company stock worth $1,797,634 over the last three months. Company insiders own 7.00% of the company’s stock.

TransMedics Group Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.